Biotech IPOs and follow-on offerings

Why biotech runs on equity, not debt

Most companies fund themselves with some mix of debt and equity, choosing the mix based on how much steady cash flow they have to service interest payments and how much risk their shareholders and lenders are willing to bear. A clinical-stage biotech mostly doesn't get to make that choice at all, because debt requires a reliable source of cash flow to service it, and a company with no approved products and years of losses ahead of it simply doesn't have that cash flow. Worse, if a key clinical trial fails, the company's value can fall sharply and quickly, which is exactly the kind of risk a lender has no interest in underwriting. So biotech, as a sector, funds itself almost entirely through equity: an initial public offering, followed by one or more follow-on offerings over the years it takes to get a drug candidate through the rest of development, regulatory approval, and commercial launch.

This is worth understanding on its own terms, not just as a footnote to valuation. It shapes everything about how a biotech company's capital structure decisions get made, how often it needs to be in the capital markets, and how much dilution its existing shareholders should expect to absorb along the way.

The biotech IPO: pricing a story, not a financial statement

A biotech IPO looks structurally different from an IPO in most other sectors, because the company being taken public usually has no revenue and no path to profitability for years. Instead of pricing the deal off trailing financial performance, an IPO in this sector is priced almost entirely off the strength of the pipeline and the credibility of the upcoming catalysts, meaning the specific clinical trial readouts and regulatory milestones investors can expect over the following one to two years. Investors buying into a biotech IPO are, in effect, buying exposure to a defined set of binary events, and the price they're willing to pay reflects their own view of the probability those events go well, the same risk-adjusted logic covered in how biotech companies are valued.

This means the timing of a biotech IPO is unusually sensitive to where the company sits in its own development cycle. A company going public shortly before a major trial readout can command a valuation that already reflects real optimism about that readout, but it also takes on real risk of a sharp value decline if the readout disappoints shortly after new public shareholders have bought in. A company that waits until after a positive readout to go public gives up some of the upside a public investor might have paid for, but it reduces the immediate binary risk sitting right after the IPO. Bankers advising a biotech on IPO timing spend real time thinking through this tradeoff alongside the company's board and management.

Follow-on offerings: raising more capital as the runway shortens

A biotech's IPO proceeds are rarely enough to fund the company all the way to profitability, since profitability for most biotechs is years away even under an optimistic scenario. Instead, biotechs plan to return to the public markets repeatedly through follow-on offerings, additional sales of stock after the IPO, to extend their cash runway, the amount of time the company can continue operating before it runs out of cash.

The timing of a follow-on offering is a genuinely strategic decision, and it's usually built around the company's catalyst calendar. Raising capital shortly after a positive trial result lets the company sell stock at a higher price, since the market has just gotten good news, which means raising a given amount of cash requires issuing fewer new shares and causes less dilution to existing shareholders. Raising capital well before a major catalyst, by contrast, means selling stock at a lower, less catalyst-inflated price, causing more dilution for the same amount of cash raised. Waiting too long to raise, hoping for better pricing right after a catalyst, carries its own risk: if the catalyst disappoints, the company may be forced to raise capital at a much lower price, or in a worse case, run low on cash at the worst possible moment with limited negotiating leverage. Managing this balance, between raising early for safety and waiting for a better price, is one of the more consequential financial decisions a biotech's management team and board make repeatedly over the company's life.

PIPEs: private capital when public markets are a harder sell

A PIPE, a private investment in public equity, is a way for an already-public biotech to raise capital directly from a smaller group of investors, typically specialist healthcare-focused funds, rather than through a fully marketed public offering sold broadly to the market. PIPEs tend to get used when a company wants to raise capital quickly, wants more certainty of execution than a broader marketed offering can guarantee, or is raising around a period of genuine uncertainty, such as shortly before an unresolved binary catalyst, when a broad public offering might be harder to price or complete on attractive terms. The tradeoff is usually price: PIPE investors, who are taking on concentrated risk and providing certainty of execution, typically negotiate a discount to the prevailing market price in exchange for committing capital.

Crossover rounds: bridging private and public

A crossover round is a late-stage private financing round completed shortly before a company's expected IPO, typically including some of the same specialist healthcare investors who are also active in public biotech markets. The name reflects the fact that these investors are "crossing over" from private to public investing, often continuing to hold their position through the IPO itself. From the company's perspective, a crossover round raises capital on favorable terms just ahead of going public, and having credible, sophisticated healthcare investors already committed as private shareholders can also lend credibility to the subsequent IPO process, since public investors can see that specialists who evaluated the company closely in private were willing to commit meaningful capital.

Cash runway as the metric that matters most

Ask a biotech-focused analyst what the single most important line item on a company's balance sheet is, and most will say cash, not because cash itself is interesting but because of what it implies: how much runway the company has left before it needs to raise capital again. Cash runway is typically expressed in terms of how many months or years of projected operating expenses the company's current cash balance can cover, and it's the number that determines whether a company can afford to wait for a better-priced follow-on after a catalyst, or whether it's under real pressure to raise capital regardless of near-term stock price. A company with ample runway has real negotiating leverage in deciding when and how to raise its next round. A company running low on cash has much less flexibility, and the market generally treats a cash-constrained biotech's stock more cautiously as a result, since a forced, poorly timed raise is itself a real risk to existing shareholders' value.

What this means for how biotech stocks actually trade

This financing pattern has a direct effect on how public market investors think about biotech stocks, and it's worth understanding for both interview and, later, buy-side purposes. Because a pre-catalyst, cash-constrained biotech is likely to dilute existing shareholders again before it ever reaches profitability, some investors specifically discount their valuation of such a company to account for expected future dilution, on top of discounting for the underlying clinical and regulatory risk. This is part of why matching a valuation method to a company's actual financing stage, not just its clinical stage, matters so much when pitching a healthcare stock: a thesis that ignores likely future dilution can overstate the per-share upside a stock actually offers, even if the underlying pipeline thesis is sound.

Venture debt and royalty financing as narrow exceptions

Debt isn't entirely absent from biotech financing, but it shows up in narrower, more specialized forms than in a conventional business. Venture debt is a form of lending specifically structured for early-stage companies with venture or growth equity backing, sized modestly relative to the company's cash and often structured to minimize the risk to the lender given the company's lack of steady cash flow. Royalty-based financing, covered in more depth in healthcare deal structures: licensing and milestones, lets a company monetize a royalty stream it's entitled to receive, which only works once there's an approved, sales-generating product actually producing that royalty. Both are narrower tools than the equity-based financing that dominates the sector, useful in specific situations but never a substitute for the steady access to public and private equity markets that most biotechs depend on throughout their development.

Practice question

Why does a biotech company go back to the equity markets so many times after its IPO, instead of raising debt?

Because a clinical-stage or early commercial-stage biotech typically doesn't have the steady cash flow a lender needs to see before extending debt, and its value can also drop sharply and quickly if a key trial fails, which makes it a poor credit from a lender's perspective. Equity doesn't require fixed interest payments and doesn't put the company at risk of default if a trial disappoints, so biotechs fund years of ongoing losses, covering clinical trials, regulatory costs, and eventually commercial launch spending, primarily through repeated equity issuance: the initial IPO, followed by one or more follow-on offerings timed around the company's catalyst calendar. Management teams generally try to raise follow-on capital shortly after positive news, since a higher share price means less dilution for existing shareholders to raise the same amount of cash, while waiting too long risks being forced to raise at a worse price, or at the worst possible time, if a catalyst disappoints instead. Some narrower tools exist, like venture debt for earlier-stage companies or royalty monetization once a product is already generating sales, but neither replaces the sector's fundamental reliance on equity as the primary way to stay funded.

What the interviewer is listening for: whether you connect the equity-heavy financing pattern back to the underlying cash flow and binary-risk story, rather than just stating "biotech uses equity" as a fact. A strong answer also mentions the catalyst-timing tradeoff in follow-on offerings, since that's the part that shows real understanding of how these decisions actually get made.